抗体的生物素化标记实验要点：

1. 细胞核因子/k基因结合核因子抗体品牌 如在反应混合液中有叠氮钠或游离氨基存在,会抑制标记反应。因此,蛋白质在反应前要对 0.1mol/L碳酸氢钠缓冲液或0.5mol/L硼酸缓冲液充分透析；

2.所用的NHSB及待生物素化蛋白质之间的分子比按蛋白质表面的ε-氨基的密度会有所不同,选择不当则影响标记的效率,应先用几个不同的分子比来筛选最适条件；

3.用NHSB量过量也是不利的,抗原的结合位点可能因此被封闭,导致抗体失活；

4.由于抗体的氨基不易接近可能造成生物素化不足,此时可加入去污剂如 Triton x-100, Tween20等；

5.当游离ε-氨基(赖氨酸残基的氨基)存在于抗体的抗原结合位点时,或位于酶的催化位点时,生物素化会降低或损伤抗体蛋白的结合力或活性；

6.生物素还可能与不同的功能基团,如羰基、氨基、巯基、异咪唑基及*基,也可与糖基共价结合；

7.交联反应后,应充分透析,否则,残余的生物素会对生物素化抗体与亲和素的结合产生竞争作用；

8.在细胞的荧光标记实验中,中和亲和素的本底低,但由于链霉亲和素含有少量正电荷,故对某些细胞可导致高本底。

产品订购信息：
英文名称  Anti-NFKB p65 

中文名称   细胞核因子/k基因结合核因子抗体品牌 

别    名  NFKBp65; NF-κBp65; NF-kBp65; Avian reticuloendotheliosis viral (v rel) oncogene homolog A; MGC131774; NFKB 3; NFKB3; Nuclear Factor NF Kappa B p65 Subunit; Nuclear factor of kappa light polypeptide gene enhancer in B cells 3; Nuclear Factor Of Kappa Light Polypeptide Gene Enhancer In B Cells; p65; p65 NF kappaB; p65 NFkB; RELA; Transcription Factor p65; v rel avian reticuloendotheliosis viral oncogene homolog A (nuclear factor of kappa light polypeptide gene enhancer in B cells 3 (p65)); V Rel Avian Reticuloendotheliosis Viral Oncogene Homolog A; v rel reticuloendotheliosis viral oncogene homolog A (avian); v-rel reticuloendotheliosis viral oncogene homolog A; p65NFKB; TF65_HUMAN.

浓    度   1mg/1ml

规 格  0.1ml/100μg 0.2ml/200μg

抗体来源   Rabbit

克隆类型   polyclonal

交叉反应   Human, Mouse, Rat, Chicken, Dog, Pig, Cow, Horse, Rabbit 

产品类型   一抗  

研究领域    细胞生物 免疫学 神经生物学 信号转导 细胞凋亡 转录调节因子

蛋白分子量  predicted molecular weight: 61kDa

性    状   Lyophilized or Liquid

免 疫 原 KLH conjugated synthetic peptide derived from human NFKBp65 N-terminus 

亚    型   IgG

纯化方法   affinity purified by Protein A

储 存 液   0.01M PBS, pH 7.4 with 10 mg/ml BSA and 0.1% Sodium azide

细胞核因子/k基因结合核因子抗体品牌 产品应用    WB=1:100-500 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500

（石蜡切片需做抗原修复） 

 not yet tested in other applications.

 optimal dilutions/concentrations should be determined by the end user.  

保存条件  Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. 

Important Note  This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. 

产品介绍 NF-kappa-B is a ubiquitous transcription factor involved in several biological processes. It is held in the cytoplasm in an inactive state by specific inhibitors. Upon degradation of the inhibitor, NF-kappa-B moves to the nucleus and activates transcription of specific genes. NF-kappa-B is composed of NFKB1 or NFKB2 bound to either REL, RELA, or RELB. The most abundant form of NF-kappa-B is NFKB1 complexed with the product of this gene, RELA. Four transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Sep 2011].

Function : NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimeric p65-p50 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric p65-p50 and p65-c-Rel complexes are transcriptional activators. The NF-kappa-B p65-p65 complex appears to be involved in invasin-mediated activation of IL-8 expression. The inhibitory effect of I-kappa-B upon NF-kappa-B the cytoplasm is exerted primarily through the interaction with p65. p65 shows a weak DNA-binding site which could contribute directly to DNA binding in the NF-kappa-B complex. Associates with chromatin at the NF-kappa-B promoter region via association with DDX1.Subunit : Component of the NF-kappa-B p65-p50 complex. Component of the NF-kappa-B p65-c-Rel complex. Homodimer; component of the NF-kappa-B p65-p65 complex. Component of the NF-kappa-B p65-p52 complex. May interact with ETHE1. Binds AES and TLE1. Interacts with TP53BP2. Binds to and is phosphorylated by the activated form of either RPS6KA4 or RPS6KA5. Interacts with ING4 and this interaction may be indirect. Interacts with CARM1, USP48 and UNC5CL. Interacts with IRAK1BP1 (By similarity). Interacts with NFKBID (By similarity). Interacts with NFKBIA. Interacts with GSK3B. Interacts with NFKBIB (By similarity). Interacts with NFKBIE. Interacts with NFKBIZ. Interacts with EHMT1 (via ANK repeats) (By similarity). Part of a 70-90 kDa complex at least consisting of CHUK, IKBKB, NFKBIA, RELA, IKBKAP and MAP3K14. Interacts with HDAC3; HDAC3 mediates the deacetylation of RELA. Interacts with HDAC1; the interaction requires non-phosphorylated RELA. Interacts with CBP; the interaction requires phosphorylated RELA. Interacts (phosphorylated at 'Thr-254') with PIN1; the interaction inhibits p65 binding to NFKBIA. Interacts with SOCS1. Interacts with UXT. Interacts with MTDH and PHF11. Interacts with ARRB2. Interacts with human respiratory syncytial virus (HRSV) protein M2-1. Interacts with NFKBIA (when phosphorylated), the interaction is direct; phosphorylated NFKBIA is part of a SCF(BTRC)-like complex lacking CUL1. Interacts with RNF25. Interacts (via C-terminus) with DDX1. Interacts with UFL1 and COMMD1. Interacts with BRMS1; this promotes deacetylation of 'Lys-310'. Interacts with NOTCH2 (By similarity). Directly interacts with MEN1; this interaction represses NFKB-mediated transactivation. Interacts with AKIP1, which promotes the phosphorylation and nuclear retention of RELA. Interacts (via the RHD) with GFI1; the interaction, after bacterial lipopolysaccharide (LPS) stimulation, inhibits the transcriptional activity by interfering with the DNA-binding activity to target gene promoter DNA.Subcellular Location : Nucleus. Cytoplasm. Note=Colocalized with DDX1 in the nucleus upon TNF-alpha induction. Nuclear, but also found in the cytoplasm in an inactive form complexed to an inhibitor (I-kappa-B). Colocalizes with GFI1 in the nucleus after LPS stimulation.Post-translational modifications : Ubiquitinated, leading to its proteasomal degradation. Degradation is required for termination of NF-kappa-B response.Monomethylated at Lys-310 by SETD6. Monomethylation at Lys-310 is recognized by the ANK repeats of EHMT1 and promotes the formation of repressed chromatin at target genes, leading to down-regulation of NF-kappa-B transcription factor activity. Phosphorylation at Ser-311 disrupts the interaction with EHMT1 without preventing monomethylation at Lys-310 and relieves the repression of target genes.Phosphorylation at Ser-311 disrupts the interaction with EHMT1 and promotes transcription factor activity. Phosphorylation on Ser-536 stimulates acetylation on Lys-310 and interaction with CBP; the phosphorylated and acetylated forms show enhanced transcriptional activity. Phosphorylation at Ser-276 by RPS6KA4 and RPS6KA5 promotes its transactivation and transcriptional activities.Reversibly acetylated; the acetylation seems to be mediated by CBP, the deacetylation by HDAC3 and SIRT2. Acetylation at Lys-122 enhances DNA binding and impairs association with NFKBIA. Acetylation at Lys-310 is required for full transcriptional activity in the absence of effects on DNA binding and NFKBIA association. Acetylation can also lower DNA-binding and results in nuclear export. Interaction with BRMS1 promotes deacetylation of Lys-310. Lys-310 is deacetylated by SIRT2.S-nitrosylation of Cys-38 inactivates the enzyme activity.Sulfhydration at Cys-38 mediates the anti-apoptotic activity by promoting the interaction with RPS3 and activating the transcription factor activity.Sumoylation by PIAS3 negatively regulates DNA-bound activated NF-kappa-B.Similarity : Contains 1 RHD (Rel-like) domain.Database links :Entrez Gene: 5970 HumanEntrez Gene: 19697 MouseEntrez Gene: 309165 RatOmim: 164014 HumanSwissProt: Q04206 HumanSwissProt: Q04207 MouseUnigene: 502875 HumanUnigene: 249966 MouseUnigene: 19480 Rat转录调节因子（Transcriptin Regulators）NF-κBp65是一种重要的转录因子，NF-kBp65可激活参与、细胞增殖、细胞凋亡等基因的调节，影响着细胞的凋亡，同时影响着细胞对细胞毒性药物及离子辐射的敏感性。ras基因诱导的致癌突变作用需NFkB的活化，提示NFkB在致癌发生方面可能起一定作用；另有文献报道，在、非小细胞性、、T或B淋巴细胞及诱变导致的等人类中，NFkB活化或表达。经研究认为：NFKBp65蛋白在静息状态下以结合态的方式存在于胞浆中，当NFKBp65蛋白被激活后解离进入细胞核。(NF-κB与其抑制蛋白IκB家族成员结合，以无活性的复合物形式存在于胞浆中，当细胞受到各种刺激后，NF- κB与IκB 解离，从而进入细胞核，与相应的靶序列结合，调节基因的表达)

抗体的鉴定：

1）细胞核因子/k基因结合核因子抗体品牌 抗体的效价鉴定：不管是用于诊断还是用于,制备抗体的目的都是要求较高效价。不同的抗原制备的抗体,要求的效价不一。鉴定效价的方法很多,包括有试管凝集反应,琼脂扩散试验,酶联免疫吸附试验等。常用的抗原所制备的抗体一般都有约成的鉴定效价的方法,以资比较。如制备抗抗体的效价,一般就采用琼脂扩散试验来鉴定。

2）抗体的特异性鉴定：抗体的特异性是指与相应抗原或近似抗原物质的识别能力。抗体的特异性高,它的识别能力就强。衡量特异性通常以交叉反应率来表示。交叉反应率可用竞争抑制试验测定。以不同浓度抗原和近似抗原分别做竞争抑制曲线,计算各自的结合率,求出各自在IC50时的浓度,并按公式计算交叉反应率。 

如果所用抗原浓度IC50浓度为pg/管,而一些近似抗原物质的IC50浓度几乎是无穷大时,表示这一抗血清与其他抗原物质的交叉反应率近似为0,即该血清的特异性较好。

3）抗体亲和力：是指抗体和抗原结合的牢固程度。亲和力的高低是由抗原分子的大小,抗体分子的结合位点与抗原决定簇之间立体构型的合适度决定的。有助于维持抗原抗体复合物稳定的分子间力有氢键,疏水键,侧链相反电荷基因的库仑力,范德华力和空间斥力。亲和力常以亲和常数K表示,K的单位是L/mol。抗体亲和力的测定对抗体的筛选,确定抗体的用途,验证抗体的均一性等均有重要意义。

ASM(Human acid sphingomyelinase) ELISA Kit 人酸性神经鞘磷脂酶Multi-class antibodies规格： 48T

Anti-Nociceptin receptor 孤菲肽受体/痛敏肽受体抗体Multi-class antibodies规格： 0.2ml

Rhesus antibody Rh IL-1 Beta/IL-1B 白介素1β抗体 IL-1β 规格 0.1ml

IL-1sR I ELISA Kit 大鼠白介素1可溶性受体Ⅰ 96T

Pokemon/ZBTB7 英文名称： 蒙蛋白抗体 0.1ml

Cytochrome C 英文名称： 细胞色素C抗体 0.1ml

Anti-Nociceptin receptor 孤菲肽受体/痛敏肽受体抗体Multi-class antibodies规格： 0.2ml

FE(Mouse ferritin) ELISA KIT 小鼠铁蛋白Multi-class antibodies规格： 48T

Anti-CD31/FITC 荧光素标记血小板内皮细胞黏附分子-1抗体IgGMulti-class antibodies规格： 0.2ml

Rhesus antibody Rh DVL2 蓬乱蛋白2抗体 规格 0.2ml

Rotavirus IgM 轮状病毒 IgM(间接法二步法)

MMP19 英文名称： 基质金属蛋白酶18/19 0.2ml

ADAMTS7(NT) 英文名称： 整合素样金属蛋白酶与凝血酶1型-7抗体 (N端抗体) 0.1ml

Anti-CD31/FITC 荧光素标记血小板内皮细胞黏附分子-1抗体IgGMulti-class antibodies规格： 0.2ml

Anti-GPC3/FITC 荧光素标记磷脂酰基醇蛋白聚糖-3抗体IgGMulti-class antibodies规格： 0.2ml

Anti-P38 MAPK/FITC 荧光素标记原活化蛋白激酶p38抗体IgGMulti-class antibodies规格： 0.2ml

Rhesus antibody Rh Beta-arrestin 1 β-抑制蛋白1抗体 规格 0.2ml

CR (Calretinin) 钙结合蛋白(抗原) 0.5mg

Histone H1t 英文名称： 组蛋白H1抗体 0.1ml

Rhesus antibody Rh RASA3 Ras-GTP酶激活蛋白3抗体 规格 0.2ml

Anti-P38 MAPK/FITC 荧光素标记原活化蛋白激酶p38抗体IgGMulti-class antibodies规格： 0.2ml

纤维二糖-多粘菌素E(CC)琼脂250g用于弧菌分离培养基

GAMBroth,Modified

疱肉牛肉粒 Dried Meat Particle 100 加入疱肉基础中，配成疱肉培养基

胆盐硫乳琼脂培养基250g/瓶用于肠道致病菌的选择性分离incubationmedia胆盐硫乳琼脂培养基250g/瓶用于肠道致病菌的选择性分离

MRS琼脂平板(9cm) 10个/包 用于食品中乳酸菌总数测定

ChinaBlueAgar

酪蛋白胨卵磷脂聚山梨醇脂肉汤 incubation media 酪蛋白胨卵磷脂聚山梨醇脂肉汤

胰蛋白胨大豆琼脂培养基 250g 用于普通的或营养要求较高的细菌的培养，还用于医药工业洁净室无菌程度的监测及消毒剂消毒效果的...

SD大鼠骨髓间质干细胞成骨诱导分化培养基SDratbonemarrowmesenchymalstemcellsandosteogenicdifferentiationmedium

牛津琼脂(OXA)基础 250g 用于单增李氏菌的选择性分离(SN标准)

细胞核因子/k基因结合核因子抗体品牌 玫瑰红琼脂瓶装颗粒培养基  规格：  250g  用途：  供药品和生物制品中霉菌和酵母菌的计数、分离和培养用

煌绿乳糖胆盐肉汤BGLB瓶装颗粒培养基  规格：  250g  用途：  用于多管发酵法测定大肠菌群的确证试验

缓冲蛋白胨水瓶装颗粒培养基(BPW)  规格：  250g  用途：  用于食品中沙门氏菌的前增菌培养

胆盐乳糖瓶装颗粒培养基  规格：  250g  用途：  用于药品中大肠杆菌和绿脓杆菌的增菌培养